Form 4: GoodRx Director Scott Wagner Receives Equity Grant

Director Scott Wagner was granted 73,434 restricted stock units as part of his compensation package with GoodRx Holdings, Inc.

Summary

• Director Scott Wagner acquired 73,434 restricted stock units (RSUs) on June 16, 2026.
• Each RSU represents a contingent right to receive one share of Class A common stock.
• The RSUs vest in full on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders.
• Following this transaction, the reporting person directly owns 290,097 shares and indirectly owns 182,900 shares via the Wagner Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard equity compensation disclosure.

Risks

• Vesting is subject to the reporting person's continued service through the applicable vesting date.

Future Outlook

The RSUs are expected to vest in full on the earlier of June 16, 2027, or the date of the 2027 Annual Meeting of Stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice to ensure board members maintain a vested interest in the company's long-term performance.

Comparison to Industry Standards

• The grant structure is consistent with standard equity compensation practices for publicly traded technology and healthcare companies.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation event.

Next Steps

• Vesting of the 73,434 RSUs on the earlier of June 16, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

GoodRx, GDRX, Form 4, Insider Trading, Equity Compensation, Director Compensation